Dario G.
- Country
- Italy
- Department
- Oncology
Research Overview
- Phase III Trial Comparing FOLFIRI Plus Cetuximab Versus Bevacizumab in First-Line Treatment of mCRC with RAS/BRAF Wild-Type Tissue and Mutated Liquid Biopsy
- Evaluation of Cabozantinib and Lanreotide Combination in Gastroenteropancreatic and Thoracic Neuroendocrine Tumors: A Phase II Clinical Trial
- Phase 3 Randomized Study of Elacestrant Versus Standard Endocrine Therapy in Node-Positive, ER-Positive, HER2-Negative Early Breast Cancer with High Recurrence Risk
Data & Insights
Has run more than one trial at 31 of 266 partner sites.
Specializations
Thoracic Neuroendocrine Malignancies
Clinical research in metastatic pulmonary large-cell neuroendocrine carcinoma and related thoracic neuroendocrine tumors, with emphasis on systemic treatment options for aggressive and uncommon lung cancers.
- Durvalumab with carboplatin and etoposide
- Large-cell neuroendocrine carcinoma
- Thoracic neuroendocrine tumor
Work in this area is centered on immunotherapy-based and chemotherapy-based strategies for advanced neuroendocrine disease.
Gastroenteropancreatic Neuroendocrine Tumors
Active involvement in the management of gastroenteropancreatic neuroendocrine tumors, including well-differentiated disease requiring targeted and hormonal treatment approaches.
- Cabozantinib
- Lanreotide
- Objective response rate
This research domain includes interest in molecular markers such as MET, AXL, and VEGFR2 in relation to treatment activity and safety.
Metastatic Colorectal Cancer
Clinical trial activity in metastatic colorectal cancer focuses on first-line treatment selection in patients characterized by discordant RAS/BRAF findings between tissue and liquid biopsy.
- FOLFIRI
- Cetuximab
- Bevacizumab
The therapeutic interest lies in optimizing biologic and chemotherapy combinations for advanced disease control.
Hormone Receptor-Positive Breast Cancer
Research activity also covers node-positive estrogen receptor-positive HER2-negative early breast cancer with high risk of recurrence, with attention to endocrine-based treatment strategies.
- Elacestrant
- Endocrine therapy
- Invasive breast cancer-free survival
This area reflects a therapeutic focus on recurrence prevention in early-stage hormone-sensitive breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.